Intellia Therapeutics, Inc.
NTLA
$9.06
$0.9611.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.52% | 14.99% | -13.37% | 59.55% | -16.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.52% | 14.99% | -13.37% | 59.55% | -16.77% |
| Cost of Revenue | -10.61% | -4.59% | -3.31% | 0.75% | 1.01% |
| Gross Profit | 15.51% | 6.90% | 1.98% | 4.60% | -3.47% |
| SG&A Expenses | 0.74% | 10.97% | 26.29% | 32.03% | 35.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.67% | -0.90% | 2.93% | 7.36% | 8.10% |
| Operating Income | 10.97% | 2.29% | -4.59% | -3.68% | -10.76% |
| Income Before Tax | 14.64% | 5.62% | -8.32% | -7.86% | -12.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 14.64% | 5.62% | -8.32% | -7.86% | -12.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.64% | 5.62% | -8.32% | -7.86% | -12.94% |
| EBIT | 10.97% | 2.29% | -4.59% | -3.68% | -10.76% |
| EBITDA | 11.61% | 2.39% | -4.51% | -3.49% | -10.60% |
| EPS Basic | 21.66% | 14.42% | 2.57% | 3.09% | -1.74% |
| Normalized Basic EPS | 17.16% | 11.24% | 6.89% | 9.24% | 2.71% |
| EPS Diluted | 21.66% | 14.42% | 2.57% | 3.09% | -1.74% |
| Normalized Diluted EPS | 17.16% | 11.24% | 6.89% | 9.24% | 2.71% |
| Average Basic Shares Outstanding | 9.20% | 10.36% | 11.17% | 11.34% | 11.02% |
| Average Diluted Shares Outstanding | 9.20% | 10.36% | 11.17% | 11.34% | 11.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |